Sana Biotechnology Inc vs Clear Secure Inc — how do they compare? Sana Biotechnology Inc trades at $2.84 (market cap $836.71M), while Clear Secure Inc trades at $43.61 (market cap $4.44B). The key difference: Clear Secure Inc is far larger — about 5.3× Sana Biotechnology Inc's market cap, and Clear Secure Inc pays a 1.33% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Clear Secure Inc for 19 Days on average.
| SANA | YOU | |
|---|---|---|
Market Cap | $836.71M | $4.44B |
Volume | 4,507,444 | 1,477,828 |
Sector | Health | Technology |
52-Week High | $5.92 | $62.36 |
52-Week Low | $2.68 | $29.61 |
Typical Hold Time | 23 Days | 19 Days |
Enterprise Value | $749.96M | $3.59B |
Dividend Yield | — | 1.33% |
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.83, up 4.04% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue generation, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent investor conference presentations highlight ongoing business development activities.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA carries high risk due to pre-revenue status, negative cash flow, and shareholder litigation concerns. The stock's investment case hinges on successful clinical development and future commercialization of its engineered cell therapies, requiring careful risk assessment by investors.
Clear Secure (YOU) trades at $43.26, up 1.59% today, with a bullish technical signal despite mixed moving averages. The company reported strong Q2 2026 results, beating EPS estimates with $0.49 versus $0.40 expected, and revenue growth accelerated to 27% year-over-year. Profitability remains robust with a net margin of 14.78% and ROE of 90.29%, though valuation multiples like P/E of 29.11 appear elevated. Recent news highlights strategic partnerships, such as the integration with CrowdStrike's Falcon platform, and the launch of corporate memberships.
The outlook is positive given earnings momentum and expanding market opportunities, but risks include high valuation sensitivity and competitive pressures. Analysts are generally bullish with a consensus price target of $61.40, implying significant upside, though insider selling and overbought RSI levels warrant caution for near-term volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →